Published • loading... • Updated
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
- Decoy Therapeutics, Inc. issued a correction to its September 22, 2026, press release concerning a warrant inducement transaction.
- The company clarified that new unregistered warrants covering up to 2,368,868 common shares do not require stockholder approval.
- The warrants become exercisable immediately upon issuance and expire five years after issuance.
- Decoy Therapeutics said all other information in the original press release remains unchanged.
Insights by Ground AI
24 Articles
24 Articles
The Norfolk Daily News+23 Reposted by 23 other sources
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.
Coverage Details
Total News Sources24
Leaning Left0Leaning Right2Center18Last UpdatedBias Distribution90% Center
Bias Distribution
- 90% of the sources are Center
90% Center
C 90%
Factuality
To view factuality data please Upgrade to Premium
